Details

Senhwa Biosciences, Inc. announced today that the FDA has granted Fast Track Designation for Pidnarulex, a first-in-class G-quadruplex stabilizer, for the treatment of patients with breast and ovarian cancers BRCA1/2, PALB2, or other HRD mutations.